The Dual-Antigen Ad5 COVID-19 Vaccine Delivered as an Intranasal Plus Subcutaneous Prime Elicits Th1 Dominant T-Cell and Humoral Responses in CD-1 Mice by jhollister | Mar 30, 2021
A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses. by nantkweststg | Feb 12, 2021
Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs. by nantkweststg | Feb 12, 2021
An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression. by nantkweststg | Feb 12, 2021
Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform. by nantkweststg | Feb 12, 2021
Recent Comments